How to take lazolvan tablets

Posted on by admin

Lazolvan - instructions for use, analogs, reviews and release forms (tablets 30 mg, syrup, solution for inhalation, lozenges 15 mg) of a drug for the treatment of cough and bronchitis in adults, children and pregnancy

In this article you can read the instructions for use of the drug Lazolvan.

Table of contents:

Reviews of site visitors - consumers of this medicine, as well as the opinions of specialist doctors on the use of Lazolvan in their practice are presented. We kindly ask you to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not stated by the manufacturer in the annotation. Analogues of Lazolvan in the presence of existing structural analogues. Use for the treatment of bronchitis, pneumonia and cough in adults, children, as well as during pregnancy and lactation.

Lazolvan is a mucolytic drug.

Studies have shown that ambroxol (the active ingredient of Lazolvan) increases secretion in the respiratory tract. Enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough.

Lazolvan is characterized by rapid and almost complete absorption with a linear dose dependence in the therapeutic concentration range. The transition of ambroxol from the blood to tissues when administered orally occurs quickly. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of the dose taken undergoes a first-pass effect through the liver. The remainder of ambroxol is metabolized in the liver, mainly by conjugation.

Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum:

  • acute and chronic bronchitis;
  • pneumonia;
  • chronic obstructive pulmonary disease;
  • bronchial asthma with difficulty in sputum discharge;
  • bronchiectasis.

Syrup (children's form of the drug).

Solution for oral administration and inhalation.

Instructions for use and dosage

The drug in tablet form is prescribed to adults 30 mg 3 times a day.

If necessary, to enhance the therapeutic effect, you can prescribe 60 mg 2 times a day. The tablets are taken after meals with liquid.

The drug in the form of a syrup of 15 mg/5 ml is prescribed to adults and children over 12 years of age, 10 ml (2 teaspoons) 3 times a day; children aged 6 to 12 years - 5 ml (1 teaspoon) 2-3 times a day; children aged 2 to 6 years are prescribed 2.5 ml (1/2 teaspoon) 3 times a day; children under 2 years old - 2.5 ml (1/2 teaspoon) 2 times a day.

The drug in the form of a syrup 30 mg/5 ml is prescribed to adults and children over 12 years of age 5 ml (1 teaspoon) 3 times a day; children aged 6 to 12 years - 2.5 ml (1/2 teaspoon) 2-3 times a day.

Taking the drug for more than 4-5 days is possible only under the supervision of a doctor.

Lazolvan in the form of syrup should be taken during meals with liquid.

Lazolvan in the form of an inhalation solution can be used with any modern inhalation device, except for evaporating inhalers. The drug is mixed with saline in a 1:1 ratio to achieve optimal air humidification in the respirator.

During inhalation, in order to avoid a cough reflex caused by a deep breath, the patient should breathe calmly. It is recommended to warm the inhaled solution to body temperature. Patients with bronchial asthma are recommended to take inhalations after taking bronchodilators.

  • heartburn;
  • dyspepsia;
  • nausea, vomiting;
  • diarrhea;
  • skin rash;
  • hives;
  • angioedema;
  • anaphylactic reactions (including anaphylactic shock).
  • 1st trimester of pregnancy;
  • hypersensitivity to the components of the drug.

Use during pregnancy and breastfeeding

Lazolvan penetrates the placental barrier.

Experimental studies on animals did not reveal direct or indirect adverse effects on pregnancy, embryonic, prenatal and postnatal development and childbirth.

Clinical studies during 28 weeks of pregnancy found no evidence of a negative effect of the drug on the fetus.

However, the usual precautions should be taken when using the drug during pregnancy. It is especially not recommended to take Lazolvan in the 1st trimester of pregnancy.

Ambroxol can be excreted in human milk. Therefore, it is not recommended to prescribe Lazolvan to nursing mothers. However, an adverse effect in newborns is unlikely.

Should not be used in combination with antitussives that impede the removal of sputum.

Lazolvan syrup (15 mg/5 ml) contains 10.5 g of sorbitol based on the maximum recommended daily dose (30 ml). Patients with rare hereditary fructose intolerance should not take this drug. It may also have a mild laxative effect.

Lazolvan syrup (30 mg/5 ml) contains 5 g of sorbitol based on the maximum recommended daily dose (20 ml). Patients with rare hereditary fructose intolerance should not take this drug.

Lazolvan tablets (30 mg) contain 684 mg of lactose based on the maximum recommended daily dose (120 mg). Patients with rare hereditary galactose intolerance, Lapp lactase deficiency or impaired glucose/galactose absorption should not take this drug.

Very rare cases of severe skin lesions have been reported, such as Stevens-Johnson syndrome and Lyell's syndrome; however, the relationship with the drug has not been proven. If the above syndromes develop, it is recommended to stop treatment and immediately seek medical help.

Simultaneous use with antitussive drugs leads to difficulty in sputum discharge while reducing cough.

Ambroxol increases the penetration of amoxicillin, cefuroxime, erythromycin, and doxycycline into the bronchial secretions.

Lazolvan is compatible with drugs that inhibit labor.

Analogues of the drug Lazolvan

Structural analogues of the active substance:

Source: http://instrukciya-otzyvy.ru/110-lazolvan-po-primeneniyu-analogi-tabletki-sirop-rastvor-dlya-ingalyaciy-pastilki-kashel-bronhit.html

Lazolvan

Lazolvan: instructions for use and reviews

Latin name: Lasolvan

ATX code: R05CB06

Active ingredient: ambroxol (ambroxol)

Manufacturer: Instituto De Angeli (Italy), Boehringer Ingelheim Ellas (Greece), Bolder Arzneimittel GmbH & Co. KG (Germany), Delpharm Reims (France)

Update of description and photo: 08/29/2017

Prices in pharmacies: from 156 rubles.

Lazolvan is an expectorant and mucolytic drug.

Release form and composition

Lazolvan is produced in the following dosage forms:

  • Lozenges: round, light brown, with the smell of peppermint (in blisters of 10 pcs., 1, 2 or 4 blisters in a cardboard box);
  • Tablets: round, slightly yellowish or white, flat on both sides, with beveled edges, on one side there is a separating line and the inscription “67C” embossed on both sides of it, on the other - the company symbol (in blisters of 10 pcs., 2 or 5 blisters in a cardboard box);
  • Syrup: almost colorless or colorless, almost transparent or transparent, with the smell of wild berries (15 mg/5 ml each) or strawberry smell (30 mg/5 ml each), slightly viscous (in dark glass bottles of 100, 200 or 250 ml per complete with or without a measuring cup, 1 bottle in a cardboard box);
  • Solution for oral administration and inhalation: transparent, slightly brownish or colorless (in dark glass bottles of 100 ml, complete with a dosing cup or beaker, 1 bottle in a cardboard box).

The composition of 1 lozenge Lazolvan includes:

  • Active substance: ambroxol – 15 mg (in the form of hydrochloride);
  • Auxiliary components: acacia gum – 850 mg, sorbitol – 307.4 mg, carion 83 (mannitol, sorbitol, hydrogenated hydrolyzed starch) – 614.8 mg, peppermint leaf oil – 10 mg, eucalyptus leaf oil – 2 mg, saccharin sodium – 1.8 mg, liquid paraffin (purified mixture of liquid saturated hydrocarbons) – 2.4 mg, purified water – 196.6 mg.

The composition of 1 tablet Lazolvan includes:

  • Active substance: ambroxol – 30 mg (in the form of hydrochloride);
  • Auxiliary components: lactose monohydrate – 171 mg, dried corn starch – 36 mg, colloidal silicon dioxide – 1.8 mg, magnesium stearate – 1.2 mg.

The composition of 5 ml of Lazolvan syrup includes:

  • Active substance: ambroxol – 15 or 30 mg (in the form of hydrochloride);
  • Auxiliary components (15/30 mg per 5 ml, respectively): benzoic acid - 8.5/8.5 mg, hydroxyethylcellulose (hyetellose) - 10/10 mg, acesulfame potassium - 5/5 mg, liquid sorbitol (non-crystallizing) - 1750/1750 mg, glycerol 85% – 750/750 mg, vanilla flavor – 3/3 mg, purified water – 3047.5/3031.5 mg, wild berry flavor PHL – 11 mg (for syrup 15 mg/5 ml) or strawberry-cream flavor PHL – 12 mg (for syrup 30 mg/5 ml).

The composition of 1 ml of solution for oral administration and inhalation of Lazolvan includes:

  • Active substance: ambroxol – 7.5 mg (in the form of hydrochloride);
  • Auxiliary components: citric acid monohydrate - 2 mg, sodium hydrogen phosphate dihydrate - 4.35 mg, sodium chloride - 6.22 mg, benzalkonium chloride - 0.225 mg, purified water - 989.705 mg.

Pharmacological properties

Pharmacodynamics

Research data show that ambroxol, which is the active component of Lazolvan, causes an increase in secretion in the respiratory tract. As a result of exposure to the drug, the production of pulmonary surfactant and ciliary activity are enhanced. These effects stimulate the flow and transport of mucus (mucociliary clearance), resulting in intense mucus discharge and cough relief. In the treatment of chronic obstructive pulmonary disease during long-term therapy with Lazolvan (for 2 months or more), the number of exacerbations decreased significantly. A significant decrease in the duration of exacerbations and the number of days of antibiotic therapy was recorded.

Pharmacokinetics

All dosage forms of immediate release ambroxol are characterized by rapid and almost complete absorption (a linear dependence of absorption on dose is observed). When taken orally, the maximum concentration of ambroxol in plasma is achieved after 60–150 minutes. Distribution volume – 552 l. The binding of ambroxol to plasma proteins in the therapeutic concentration range is approximately 90%.

When administered orally, the transition of the active substance from the blood to the tissues occurs quickly. The highest concentrations of ambroxol are observed in the lungs. About 30% of an oral dose undergoes a first pass process through the liver. Studies on human liver microsomes have proven that the predominant isoform is the CYP3A4 isoenzyme. It is responsible for the metabolism of the active substance to dibromanthranilic acid. The remaining amount is metabolized in the liver, mostly by glucuronidation and through partial degradation (approximately 10%) to dibromoantranilic acid and additional metabolites in small quantities. The terminal half-life is 10 hours. Total clearance is up to 660 ml/min, with about 8% of the total clearance being renal clearance. In studies using the radioactive tracer method, it was calculated that as a result of taking a single dose of ambroxol over the next 5 days, approximately 83% of the dose taken is excreted in the urine.

A clinically significant effect of gender and age on the pharmacokinetics of ambroxol has not been recorded, so there is no reason to select the dosage based on these characteristics.

Indications for use

Lazolvan is prescribed for the treatment of the following acute and chronic diseases of the respiratory tract, which occur with the release of viscous sputum:

  • Bronchiectasis;
  • Pneumonia;
  • Bronchitis in acute and chronic course;
  • Bronchial asthma, occurring with difficulty in sputum discharge;
  • Chronic obstructive pulmonary disease.

Contraindications

  • First trimester of pregnancy and lactation period;
  • Hypersensitivity to the components of the drug.

Lazolvan should be used with caution in pregnant women in the second and third trimesters, as well as in those with renal and/or liver failure.

Children, depending on the dosage form of Lazolvan, can take:

  • Lozenges and syrup 30 mg/5 ml: from 6 years;
  • Tablets: from 18 years of age.

The lozenges, based on the maximum recommended daily dose (90 mg), contain 3200 mg of sorbitol, so patients with rare hereditary fructose intolerance should not take Lazolvan in this dosage form.

Lazolvan in tablet form is contraindicated for patients with lactase deficiency, lactose intolerance and glucose-galactose malabsorption.

Lazolvan syrup should not be taken by patients with hereditary fructose intolerance.

Instructions for use of Lazolvan: method and dosage

Lazolvan is used orally or inhaled.

The drug can be taken orally regardless of the time of meal.

Lozenges should be slowly dissolved in the mouth, tablets should be taken with liquid, the solution can be diluted in juice, tea, milk or water.

As a rule, Lazolvan is prescribed orally:

  • Lozenges: adults and children over 12 years old – 3 times a day, 2 lozenges; children 6-12 years old – 2-3 times a day, 1 lozenge;
  • Tablets: 3 times a day, 1 tablet; to enhance the therapeutic effect, it is possible to increase the daily dose (2 times a day, 2 tablets);
  • Syrup 15 mg/5 ml: adults and children over 12 years old – 3 times a day, 10 ml; children 6-12 years old – 2-3 times a day, 5 ml; children 2-6 years old – 3 times a day, 2.5 ml; children under 2 years old – 2.5 ml 2 times a day;
  • Syrup 30 mg/5 ml: adults and children over 12 years old – 3 times a day, 5 ml; children 6-12 years old – 2-3 times a day, 2.5 ml;
  • Oral solution (1 ml = 25 drops): adults and children over 12 years old – 3 times a day, 100 drops; children 6-12 years old – 2-3 times a day, 50 drops; children 2-6 years old – 3 times a day, 25 drops; children under 2 years old – 2 times a day, 25 drops.

Inhalation Lazolvan is usually prescribed:

  • Adults and children over 6 years old – 1-2 inhalations of 2-3 ml of solution per day;
  • Children under 6 years old – 1-2 inhalations of 2 ml of solution per day.

For inhalation, you can use any modern equipment designed for this (except for steam inhalers). To ensure optimal hydration during inhalation, Lazolvan should be mixed with a 0.9% sodium chloride solution in a 1:1 ratio. Since during inhalation therapy a deep breath can lead to the development of a cough, inhalations must be carried out while maintaining a normal breathing rhythm. Before the procedure, it is recommended to warm the Lazolvan inhalation solution to body temperature. Patients with bronchial asthma are recommended to carry out inhalation after taking bronchodilator drugs, which will help avoid nonspecific irritation of the respiratory tract and their spasm.

If symptoms of the disease persist for 4-5 days from the start of taking Lazolvan, it is recommended to consult a doctor.

Side effects

As a rule, Lazolvan is well tolerated.

The following side effects may develop during therapy:
  • Gastrointestinal tract: often - nausea, decreased sensitivity in the esophagus or mouth; uncommon – diarrhea, dyspepsia, heartburn, vomiting, pain in the upper abdomen, dry mucous membrane of the throat and mouth;
  • Nervous system: often – disturbance of taste sensations;
  • Immune system, skin and subcutaneous tissues: rarely - urticaria, rash, angioedema, anaphylactic reactions (including anaphylactic shock), itching and other allergic reactions.

Overdose

Specific symptoms of Lazolvan overdose in humans have not been described.

There is evidence of a medical error and/or accidental overdose, as a result of which symptoms of side effects known for this drug were recorded: dyspepsia, nausea, vomiting, diarrhea, abdominal pain. In some cases, there is a need for symptomatic therapy.

Treatment: you should artificially induce vomiting, rinse the stomach for 1-2 hours after taking the drug. Symptomatic therapy is also indicated.

special instructions

Lazolvan should not be combined with antitussive drugs that impede the removal of sputum.

In patients with severe skin lesions (toxic epidermal necrolysis or Stevens-Johnson syndrome), the early phase may include fever, rhinitis, body pain, sore throat and cough. During symptomatic therapy, it is possible to erroneously prescribe mucolytic drugs such as Lazolvan. There are isolated reports of the detection of toxic epidermal necrolysis and Stevens-Johnson syndrome, which coincided with its administration, but there is no cause-and-effect relationship with the use of Lazolvan.

If the above syndromes develop, you should stop using the drug and immediately seek help from a doctor.

In case of functional disorders of the kidneys, Lazolvan can be used only as prescribed by a doctor.

1 tablet contains 162.5 mg of lactose, in the maximum daily dose (4 tablets) – 650 mg of lactose.

The sorbitol contained in the syrup may have a slight laxative effect. The maximum recommended daily dose of syrup contains 5 g (in 20 ml of syrup 30 mg/5 ml) or 10.5 g (in 30 ml of syrup 15 mg/5 ml) of sorbitol.

The solution for oral administration and inhalation contains the preservative benzalkonium chloride, which during inhalation can cause bronchospasm in patients with increased respiratory tract reactivity. The solution is not recommended to be mixed with alkaline solutions and cromoglycic acid. An increase in the pH value of the solution above 6.3 may lead to precipitation of the active substance or the appearance of opalescence.

Patients who follow a low-sodium diet should take into account that the recommended daily dose (for adults and children over 12 years of age) of Lazolvan in the form of a solution for oral administration and inhalation contains 42.8 mg of sodium.

Use during pregnancy and lactation

Ambroxol penetrates the placental barrier. Preclinical studies did not reveal any direct or indirect adverse effects of the drug on the course of pregnancy, embryonic/fetal, postnatal development and labor.

Extensive clinical experience with the use of the drug from the 28th week of pregnancy has shown no evidence of a negative effect of the drug on the fetus, however, when using Lazolvan during pregnancy, the usual precautions should be followed. The drug is not recommended to be taken in the first trimester of pregnancy. Use in the second or third trimesters is allowed only in cases where the possible risk to the fetus is lower than the potential benefit to the mother.

Ambroxol is excreted in breast milk. There is no data on the development of undesirable effects in children who were breastfed, however, it is not recommended to use Lazolvan during lactation.

Preclinical studies of ambroxol did not reveal any negative effects on fertility.

Use in childhood

When treating children under 12 months of age, Lazolvan is used only in the form of a solution. In such cases, it is necessary to ensure constant medical supervision.

According to the instructions, Lazolvan in the form of tablets is prohibited for use in the treatment of children under the age of 18 years, in the form of lozenges - up to 6 years.

For impaired renal function

In case of renal failure, the drug should be used with caution.

For liver dysfunction

In case of liver failure, the drug should be used with caution.

Drug interactions

There are no data on undesirable clinically significant interactions of Lazolvan with other drugs.

Lazolvan increases the penetration of drugs such as cefuroxime, amoxicillin and erythromycin into the bronchial secretions.

Analogs

Analogs of Lazolvan are: Ambroxol, Ambroxol Vramed, Ambrobene, Medox, Ambrohexal, Bronchorus, Halixol, Flavamed, Lazolvan Uno.

Terms and conditions of storage

Store in a place protected from light, out of reach of children.

  • Lozenges – 3 years at temperatures up to 30 °C;
  • Tablets – 5 years at temperatures up to 30 °C;
  • Syrup – 3 years at temperatures up to 25 °C;
  • Solution for oral administration and inhalation – 5 years at temperatures up to 25 °C.

Conditions for dispensing from pharmacies

Available without a prescription.

Reviews about Lazolvan

Reviews about Lazolvan are mostly positive. Users note that within a few days after taking the drug, there is an improvement in bronchitis and other diseases. According to reviews from parents, Lazolvan in the form of an inhalation solution and syrup has proven itself well in the treatment of children.

Also, some users report the development of side effects (diarrhea, allergic skin reactions).

Price for Lazolvan in pharmacies

The approximate price for Lazolvan is:

  • lozenges (20 pcs per pack) – 211 rubles;
  • tablets: 50 pcs. – 290 rub., 20 pcs. – 170 rub.;
  • syrup in 100 ml bottles: 15 mg/5 ml – 215 rubles, 30 mg/5 ml – 280 rubles;
  • solution for oral administration and inhalation 7.5 mg/ml in 100 ml bottles – 380 rub.

Lazolvan tablets 30 mg 20 pcs.

Lazolvan tab. 30mg n20

Lazolvan 15 mg No. 20 lozenges

Lazolvan 30 mg No. 20 tablets

Lazolvan tablets 30 mg n20

Lazolvan Max capsules 75 mg 10 pcs.

Lazolvan syrup 15 mg/5 ml 100 ml

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes and does not replace official instructions. Self-medication is dangerous to health!

The rarest disease is Kuru disease. Only members of the For tribe in New Guinea suffer from it. The patient dies of laughter. The disease is believed to be caused by eating human brains.

According to WHO research, talking on a mobile phone for half an hour every day increases the likelihood of developing a brain tumor by 40%.

American scientists conducted experiments on mice and came to the conclusion that watermelon juice prevents the development of vascular atherosclerosis. One group of mice drank plain water, and the second group drank watermelon juice. As a result, the vessels of the second group were free of cholesterol plaques.

There are very interesting medical syndromes, for example, compulsive swallowing of objects. One patient suffering from this mania had 2,500 foreign objects in her stomach.

During operation, our brain expends an amount of energy equal to a 10-watt light bulb. So the image of a light bulb above your head at the moment an interesting thought arises is not so far from the truth.

If your liver stopped working, death would occur within 24 hours.

The average life expectancy of left-handers is shorter than that of right-handers.

A person taking antidepressants will, in most cases, become depressed again. If a person has coped with depression on his own, he has every chance to forget about this condition forever.

The liver is the heaviest organ in our body. Its average weight is 1.5 kg.

The first vibrator was invented in the 19th century. It was powered by a steam engine and was intended to treat female hysteria.

Even if a person's heart does not beat, he can still live for a long period of time, as the Norwegian fisherman Jan Revsdal demonstrated to us. His “engine” stopped for 4 hours after a fisherman got lost and fell asleep in the snow.

Human blood “runs” through the vessels under enormous pressure and, if their integrity is violated, it can shoot at a distance of up to 10 meters.

An educated person is less susceptible to brain diseases. Intellectual activity promotes the formation of additional tissue that compensates for the disease.

The well-known drug Viagra was originally developed for the treatment of arterial hypertension.

The human brain weighs about 2% of the total body weight, but it consumes about 20% of the oxygen entering the blood. This fact makes the human brain extremely susceptible to damage caused by a lack of oxygen.

Omissions, disagreements, maiden name... Women's jealousy is a mystery for psychologists. Today, scientists do not fully know all the mechanisms that give rise to this strong and ra.

Source: http://www.neboleem.net/lazolvan.php

How to take Lazolvan tablets

The content of the article

The white or yellowish tablets have a round, flattened shape, beveled at the edges, with carved company symbols on one side and a demarcation strip and engraving on the other. Lazolvan contains the substance ambroxol hydrochloride - 30 mg in one tablet, which is aimed at producing and liquefying mucus in the lungs. In addition to ambroxol, each tablet contains lactose monohydrate 171 mg, corn starch 36 mg, colloidal silicon dioxide 1.8 mg and magnesium stearate 1.2 mg. By stimulating ciliary activity and increasing secretion, the medicine facilitates coughing, increases the amount of mucus inside the respiratory tract, which promotes more active sputum discharge. People with chronic lung disease noticed an improvement in their condition and a reduction in repeated attacks of the disease after 2 months of using Lazolvan.

What effect does the drug have on the body?

Depending on the dose, ambroxol guarantees rapid and complete absorption into the blood within 2 – 2.5 hours. A large amount of the drug (approximately 30%) passes through the liver, which contains the enzyme Cytochrome P450-ZA4. Cytochrome plays an important role in the human body, oxidizing molecules of foreign chemicals (medicinal impurities) and bringing them to the surface. The remainder of the chemical drugs (10% ambroxol) remains in the liver and is broken down or metabolized by joining homologous chromosomes. The drug is completely eliminated from the body after 10 hours.

Treatment with Lazolvan is prescribed to people with diseases such as:

  • Acute bronchitis;
  • Bronchial asthma;
  • Chronic lung disease;
  • Pneumonia;
  • Deformation, suppuration of the bronchi.

Before starting treatment, consult your doctor. An adult is prescribed 1 tablet of Lazolvan three times a day. The medicine is washed down with water, before or after meals. Sometimes the dose is increased. Do not self-medicate without establishing a correct diagnosis; neglect of your health can lead to adverse consequences.

Contraindications

Lazolvan tablets are not recommended for women in the 1st trimester of pregnancy, as well as during breastfeeding. During the 2nd and 3rd semesters of pregnancy, the drug is prescribed only when necessary and after the doctor’s permission. "Lazolvan" is contraindicated for children and adolescents up to adulthood. A special form has been released for them in the form of baby syrup. Avoid the substance at the first sign of intolerance or kidney or liver problems. In case of acute bullous lesions of the mucous membranes and skin (a pronounced inflamed allergic rash), the temperature may rise, painful sensations in the body may occur, the cough may intensify, and the nasopharyngeal mucosa may become inflamed. Side effects include nausea, dizziness, vomiting, loose stools, gastrointestinal disturbances, allergic skin rashes, itching, and rarely, shock reactions, anaphylaxis. No overdoses of the drug have been observed, but in case of unpleasant symptoms it is necessary to perform gastric lavage, induce vomiting, and drink activated charcoal.

It is not recommended to combine the medicine with other antitussive drugs.

The shelf life of Lazolvan in tablets is no more than 5 years. It is better to store in a dark, cool place at a temperature no higher than 30 degrees Celsius, away from children.

Source: http://www.kakprosto.ru/kakkak-prinimat-lazolvan-v-tabletkah-

Lazolvan tablets - official instructions for use

Registration number:

Tradename:

International nonproprietary name:

Dosage form:

Compound:

active substance - ambroxol hydrochloride 30 mg;

excipients - lactose monohydrate 171 mg, dried corn starch 36 mg, colloidal silicon dioxide 1.8 mg, magnesium stearate 1.2 mg.

Description:

Pharmacotherapeutic group

Expectorant, mucolytic agent

ATX Code:

pharmachologic effect

Studies have shown that ambroxol, the active ingredient in Lazolvan, increases secretion in the respiratory tract. It enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough. In patients with chronic obstructive pulmonary disease, long-term therapy with Lazolvan (for at least 2 months) led to a significant reduction in the number of exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.

All dosage forms of immediate release ambroxol are characterized by rapid and almost complete absorption with a linear dependence on the dose in the therapeutic concentration range. The maximum plasma concentration (Cmax) after oral administration is achieved after 1-2.5 hours. The absolute bioavailability of Lazolvan 30 mg tablets is 79%. The distribution volume is 552 l. In the therapeutic concentration range, binding to plasma proteins is approximately 90%. The transition of ambroxol from the blood to tissues when administered orally occurs quickly. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of an oral dose is subject to first pass effects through the liver.

Studies on human liver microsomes have shown that CYP3A4 is the predominant isoform responsible for the metabolism of ambroxol to dibromoantranilic acid. The remainder of ambroxol is metabolized in the liver, mainly by glucuronidation and by partial degradation to dibromoantranilic acid (approximately 10% of the administered dose), as well as a small number of additional metabolites.

The terminal half-life of ambroxol is about 10 hours. The total clearance is within 660 ml/min, renal clearance accounts for approximately 83% of the total clearance.

No clinically significant effect of age and gender on the pharmacokinetics of ambroxol was found, so there is no basis for selecting the dosage based on these characteristics.

Indications for use

Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.

Contraindications

Hypersensitivity to ambroxol or other components of the drug, pregnancy (first trimester), lactation period, children under 18 years of age, lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Use Lazolvan with caution during pregnancy (II - III trimester), with renal and/or liver failure.

Use during pregnancy and breastfeeding

Ambroxol penetrates the placental barrier. Preclinical studies have not revealed direct or indirect adverse effects on pregnancy, embryonic/fetal, postnatal development and labor. Extensive clinical experience with the use of ambroxol after the 28th week of pregnancy has found no evidence of a negative effect of the drug on the fetus.

However, normal precautions must be taken when using the medicine during pregnancy. It is especially not recommended to take Lazolvan in the first trimester of pregnancy.

In the second and third trimesters of pregnancy, the use of the drug is possible only if the potential benefit to the mother outweighs the potential risk to the fetus.

Ambroxol can be excreted in breast milk. Despite the fact that no undesirable effects were observed in breast-fed children, it is not recommended to use Lazolvan tablets during lactation.

Preclinical studies of ambroxol did not reveal any negative effects on fertility.

Directions for use and doses

30 mg (1 tablet) 3 times a day. If necessary, to enhance the therapeutic effect, you can prescribe 60 mg (2 tablets) 2 times a day. The drug is taken with liquid.

You can take the tablets regardless of meals.

If symptoms of the disease persist within 4-5 days from the start of treatment, it is recommended to consult a doctor.

Side effect

Gastrointestinal disorders

Often (1.0-10.0%) - nausea;

Uncommon (0.1-1.0%) - dyspepsia, vomiting, diarrhea, abdominal pain.

Immune system disorders, skin and subcutaneous tissue disorders

Rarely (0.01-0.1%) - rash, urticaria; angioedema*, anaphylactic reactions (including anaphylactic shock)*, itching*, hypersensitivity*

*these adverse reactions were observed with widespread use of the drug; with a 95% probability, the frequency of these adverse reactions is uncommon (0.1%-1.0%), but possibly lower; The exact frequency is difficult to estimate as they have not been reported in clinical studies.

Overdose

Specific symptoms of overdose in humans have not been described. There have been reports of accidental overdose and/or medical error resulting in symptoms of known side effects of Lazolvan: nausea, dyspepsia, vomiting, abdominal pain. In this case, there may be a need for symptomatic therapy.

Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug, symptomatic therapy.

Interaction with other drugs

No clinically significant, undesirable interactions with other drugs have been reported. Increases the penetration of amoxicillin, cefuroxime, and erythromycin into the bronchial secretions.

special instructions

It should not be combined with antitussives that make it difficult to remove sputum.

One tablet contains 162.5 mg of lactose. The maximum daily dose (4 tablets) contains 650 mg of lactose.

In patients with severe skin lesions - Stevens-Johnson syndrome or toxic epidermal necrolysis - fever, body pain, rhinitis, cough and sore throat may appear in the early phase.

During symptomatic treatment, it is possible to erroneously prescribe mucolytic drugs such as ambroxol. There are isolated reports of the detection of Stevens-Johnson syndrome and toxic epidermal necrolysis, which coincided with the administration of the drug; however, there is no causal relationship with the drug.

If the above syndromes develop, it is recommended to stop treatment and immediately seek medical help.

If renal function is impaired, Lazolvan should be used only on the recommendation of a doctor. For children under 18 years of age, it is possible to use other dosage forms of Lazolvan (syrup, lozenges, solution for oral administration and inhalation).

The effect of the drug on the ability to drive vehicles and machinery

Release form

10 tablets in a blister pack (blister) made of PVC/Al foil. 2 or 5 blisters with instructions for use in a cardboard pack.

Storage conditions

Keep out of the reach of children.

Best before date

Do not use after the expiration date stated on the packaging.

Source: http://medi.ru/instrukciya/lazolvan-tabletki_6832/

Lazolvan

Instructions for use:

Prices in online pharmacies:

Lazolvan is a mucolytic and expectorant drug.

Release form and composition

  • Solution for oral administration and inhalation: transparent, colorless or with a slight brownish tint (100 ml in dark glass bottles equipped with a dropper, 1 bottle in a cardboard box complete with a measuring cup);
  • Syrup: slightly viscous, colorless or almost colorless, transparent or almost transparent, with the smell of wild berries or strawberries (100 or 200 ml in dark glass bottles, 1 bottle in a cardboard box complete with a measuring cap);
  • Tablets: flat on both sides, round, with beveled edges, white or with a yellowish tint, on one side - the company symbol, on the other - a separating line and engraving “67C” on both sides of it (10 pieces in blisters, in a cardboard box 2 or 5 blisters);
  • Lozenges: round, light brown, with the smell of peppermint (10 pieces in blisters, 1, 2 or 4 blisters in a cardboard pack).

The active ingredient of the drug is ambroxol hydrochloride:

  • 1 ml of solution – 7.5 mg;
  • 5 ml of syrup – 15 or 30 mg;
  • 1 tablet – 30 mg;
  • 1 lozenge – 15 mg.
  • Solution: sodium hydrogen phosphate dihydrate, benzalkonium chloride, citric acid monohydrate, sodium chloride, purified water;
  • Syrup: purified water, hyaetellose (hydroxyethylcellulose), benzoic acid, liquid sorbitol (non-crystallizing), acesulfame potassium, glycerol 85%, vanilla flavor, wild berry flavor PHL (in syrup 15 mg/5 ml) or strawberry-cream flavor PHL (in syrup 30 mg/5 ml);
  • Tablets: dried corn starch, lactose monohydrate, colloidal silicon dioxide, magnesium stearate;
  • Lozenges: acacia gum, sorbitol, liquid paraffin (purified mixture of liquid saturated hydrocarbons), carion 83 (mannitol, sorbitol, hydrolyzed hydrogenated starch), sodium saccharinate, purified water, oil of peppermint leaves and eucalyptus leaves.

Indications for use

Lazolvan is used to treat the following acute and chronic diseases of the respiratory tract, which are accompanied by impaired mucociliary clearance and the production of viscous sputum:

  • Bronchiectasis;
  • Acute and chronic bronchitis;
  • Chronic obstructive pulmonary disease;
  • Pneumonia;
  • Bronchial asthma with difficulty in sputum discharge.

Contraindications

For all dosage forms:

  • First trimester of pregnancy;
  • Breastfeeding period;
  • Hypersensitivity to ambroxol or auxiliary components.

Additional contraindications depending on the dosage form:

  • Syrup: children under 6 years of age (for syrup at a dose of 30 mg/5 ml), hereditary fructose intolerance;
  • Tablets: age under 18 years, lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
  • Lozenges: children under 6 years of age, hereditary fructose intolerance.

Lazolvan is used with caution in the second and third trimesters of pregnancy, as well as in case of renal and/or liver failure.

Directions for use and dosage

Lazolvan solution is intended for oral administration and inhalation.

You can take it orally, regardless of food intake; if necessary, dilute it in water, juice, tea or milk.

  • Children under 2 years old – 1 ml 2 times a day;
  • Children 2-6 years old – 1 ml 3 times a day;
  • Children 6-12 years old – 2 ml 2-3 times a day;
  • Children over 12 years of age and adults – 4 ml 3 times a day.

1 ml of solution = 25 drops.

For inhalation, Lazolvan can be used using any modern inhalation equipment, with the exception of steam inhalers. To achieve optimal hydration, the solution is mixed with 0.9% sodium chloride solution in a 1:1 ratio. Inhalations should be carried out in normal breathing mode, since deep inhalation can cause coughing. Before the procedure, it is recommended to warm the drug to body temperature.

Patients with bronchial asthma should inhale Lazolvan after taking a bronchodilator, otherwise nonspecific irritation of the respiratory tract and their spasm may occur.

  • Children under 6 years of age – 2 ml of solution per inhalation, 1-2 inhalations per day;
  • Children over 6 years of age and adults – 2-3 ml of solution per inhalation, 1-2 inhalations per day.

In the form of syrup, Lazolvan is taken orally, regardless of food intake.

Recommended doses for 15 mg/5 ml syrup:

  • Children under 2 years old – 2.5 ml 2 times a day;
  • Children 2-6 years old – 2.5 ml 3 times a day;
  • Children 6-12 years old – 5 ml 2-3 times a day;
  • Children over 12 years of age and adults – 10 ml 3 times a day.

Recommended doses for 30 mg/5 ml syrup:

  • Children 6-12 years old – 2.5 ml 2-3 times a day;
  • Children over 12 years of age and adults – 5 ml 3 times a day.

Lazolvan tablets should be taken orally with liquid, regardless of meals. The drug is prescribed 1 tablet 3 times a day. To enhance the therapeutic effect, you can take 2 tablets 2 times a day.

Lazolvan lozenges should be slowly dissolved in the mouth, regardless of food intake, children aged 6-12 years - 1 piece. 2-3 times a day, children over 12 years old and adults – 2 pcs. 3 times a day.

If symptoms of the disease persist after 4-5 days of treatment, you should consult a doctor.

Side effects

  • Digestive system: often (1-10%) – decreased sensitivity in the oral cavity or pharynx, nausea; uncommon (0.1-1%) – dry mouth, abdominal pain, diarrhea, vomiting, dyspepsia; rarely (0.01-0.1%) – dry throat;
  • Nervous system: often – disturbance of taste sensations;
  • Immune system, skin and subcutaneous tissues: rarely - rash, urticaria, itching, angioedema, hypersensitivity, anaphylactic reactions (including anaphylactic shock).

special instructions

The solution contains benzalkonium chloride as a preservative; when inhaled, it can cause bronchospasm in sensitive patients with increased respiratory tract reactivity.

Lazolvan should not be mixed with alkaline solutions and cromoglycic acid, since increasing the pH value of the solution above 6.3 can lead to precipitation of ambroxol or the appearance of opalescence.

Patients on a low-sodium diet should note that the oral and inhalation solution contains 42.8 mg sodium at the recommended daily dose for children over 12 years of age and adults (12 ml).

One Lazolvan tablet contains 162.5 mg of lactose, the maximum daily dose (4 tablets) is 650 mg.

Syrup Lazolvan 30 mg/5 ml in terms of the maximum daily dose (20 ml) contains 5 g of sorbitol, Lazolvan 15 mg/5 ml in the maximum daily dose (30 ml) - 10.5 g. Due to the sorbitol content, the syrup may have mild laxative effect.

Like any expectorant, Lazolvan should not be used simultaneously with antitussives that make it difficult to remove sputum.

Patients with severe skin lesions (eg, toxic epidermal necrolysis and Stevens-Johnson syndrome) may initially develop fever, rhinitis, body pain, sore throat, and cough. During symptomatic therapy, ambroxol hydrochloride may be prescribed erroneously. There are isolated reports of the detection of such severe lesions that coincided with the use of Lazolvan, but there is no cause-and-effect relationship with the drug. Therefore, if the described symptoms develop, you should stop treatment with ambroxol and immediately consult a doctor.

Studies have not been conducted on the effect of Lazolvan on a person’s ability to perform activities related to reaction speed and increased concentration. However, no cases of negative effects were identified.

Drug interactions

There have been no reports of clinically significant, undesirable interactions between ambroxol hydrochloride and other drugs.

Ambroxol enhances the penetration of erythromycin, amoxicillin and cefuroxime into the bronchial secretions.

Terms and conditions of storage

Store in a place protected from light and out of reach of children at temperatures: solution and syrup - up to 25 ºС, tablets and lozenges - up to 30 ºС.

The shelf life of the solution and tablets is 5 years, syrup and lozenges are 3 years.

Found an error in the text? Select it and press Ctrl + Enter.

Lazolvan tablets 30 mg 20 pcs.

Lazolvan tab. 30mg n20

Lazolvan 15 mg No. 20 lozenges

Lazolvan 30 mg No. 20 tablets

Lazolvan tablets 30 mg n20

Lazolvan Max capsules 75 mg 10 pcs.

Lazolvan syrup 15 mg/5 ml 100 ml

Lazolvan is a mucolytic and expectorant drug. Form c. more details

Diazolin is an antihistamine drug belonging to the group. more details

Gelomirtol is a drug used for... more details

Atoxil is a medicine that has a bacteriostatic effect on wounds. more details

Amiksin is an antiviral and immunostimulating drug. F. more details

Lincomycin is a drug with an antibacterial effect. Form . more details

Medical reference book spravka03.net © 2018

When using materials from the site, the active reference is obligatory

Source: http://spravka03.net/lazolvan.html

Lazolvan tablets: instructions for use for children and adults

Lazolvan is included in the group of mucolytic and expectorant drugs. Available in syrup and tablet form. The product can be taken by both adults and children.

Composition and pharmacological action

Release form: tablets are whitish-yellow in color, round in shape, flattened on both sides, beveled at the edges. On one side there is a dividing strip and the inscription “67C”, on the other there is the manufacturer’s logo.

  • Lactose
  • Corn starch
  • Magnesium stearate
  • Silica

Lazolvan belongs to the group of mucolytics, i.e. it changes the physical and chemical properties of sputum, which leads to its dilution. The drug is sold in blisters of ten tablets, packed in a cardboard box. There are two or five blisters in one package.

Studies show that ambroxol increases the secretory activity of the respiratory tract, stimulates the production of pulmonary surfactant and increases the activity of the ciliated epithelium.

These actions cause increased outflow and removal of mucus (mucociliary clearance). After taking the drug, significant cough relief is also noted.

Ambroxol is quickly and almost completely absorbed. The rate of absorption depends on the amount of the drug taken, not exceeding the therapeutic dose.

The maximum plasma concentration occurs within minutes. In therapeutic doses, the connection with blood proteins reaches 90%.

The active substance, when taken orally, quickly enters the tissues. The highest content of the active component is observed in the lungs.

About 1/3 of the dose taken initially passes through the liver. During experiments on hepatocyte microsomes, it was established that CYP3A4 is the predominant isoform responsible for metabolic processes in the active substance. Residues of the active component are metabolized in the liver mainly through conjugation.

The half-life of the active substance is about ten hours. The total purification rate is about 660 ml per minute, about 8% of Ambroxol is excreted through the kidneys.

Thus, choosing a dose based on these parameters can be considered inappropriate.

Indications and contraindications

The main indications for use are pathologies of the respiratory system with the formation of thick secretions:

  • acute bronchitis, chronic form of the disease;
  • pneumonia;
  • COPD (obstructive pulmonary disease);
  • bronchial asthma with difficulty removing secretions;
  • BEB (bronchiectasis).
  • first three months of pregnancy;
  • individual intolerance to the components included in the composition.

The drug is prescribed with caution for renal and liver failure.

How to take for adults

Take 30 mg (one tablet) three times a day. On the recommendation of a doctor, for a quick onset of effect, you can take 60 mg (two tablets) at a time; the number of doses per day in this case is reduced to two times.

The tablets are taken after meals with water.

Duration of treatment is up to five days. Further use is possible only under medical supervision.

Instructions for use for children

The tablet form of Lazolvan is not suitable for children under six years of age. At this age, it is recommended to take the drug in the form of syrup (15 mg/ml), inhalation and oral solution.

Use during pregnancy and lactation

The active substance easily overcomes the placental barrier, however, during experiments on animals, no harmful effects on the course of pregnancy or labor were detected.

Clinical observations were also carried out on pregnant women who took Lazolvan for four weeks. No data on teratogenic (detrimental to the fetus) effects were obtained.

Despite this, standard precautions should be observed when using the product during pregnancy. Taking Lazolvan in the first trimester is not recommended at all.

The active substance passes into breast milk, so Lazolvan is not prescribed to nursing women (even though a negative effect on newborns is unlikely).

Side effects and overdose

As a rule, Lazolvan is well tolerated, but some patients still experience minor side effects.

The following phenomena are possible from the digestive system:

  • heartburn;
  • dyspeptic disorders;
  • nausea;
  • vomit;
  • loose stool.

In case of individual intolerance to the components, allergic reactions may develop:

  • skin rashes;
  • hives;
  • Quincke's edema;
  • anaphylactic manifestations (anaphylactic shock, etc.).

No cases of overdose have been reported to date.

In this case, the patient must induce vomiting; gastric lavage is indicated in the first two hours. After the consumption of fat-containing foods is recommended, symptomatic treatment is prescribed.

Drug interactions and special instructions

Simultaneous use with antitussives makes it difficult to remove sputum. This effect is explained by the suppression of the cough reflex and, as a result, a slowdown in the discharge of mucus.

It should be taken into account that the active component promotes the active penetration of a number of antibiotics (amoxicillin, erythromycin, etc.) into the bronchial secretions.

The product can be used simultaneously with drugs that slow down labor.

Persons taking syrup (15 mg/5 ml) should note that 30 ml of the drug contains 10.5 g of sorbitol. For this reason, the product is not suitable for those who suffer from hereditary fructose intolerance. The syrup may also have a slight laxative effect.

The recommended daily dose of tablets (120 mg) contains 684 mg of lactose. Persons suffering from hereditary galactose intolerance should not take the product.

Severe, extremely rare skin lesions (Lyell's syndrome and Stevens-Johnson syndrome) have been reported during treatment with Lazolvan, but their direct relationship to treatment with the drug has not been proven.

It has been established that Lazolvan causes an increase in the concentration of the antibacterial agent in the alveoli and bronchial mucosa, thereby improving the course of the disease in bacterial lung lesions.

Thus, the combined use of Lazolvan with antibiotics undoubtedly has advantages over antibiotic therapy alone.

During treatment with Lazolvan, a significant improvement in external respiration function in patients with broncho-obstructive syndrome, as well as a decrease in hypoxemia, has been proven.

The drug can be taken together with beta-2 adrenergic agonists in the same nebulizer chamber.

Instructions for using the drug Carniton are in this article.

You can learn about chronic pancreatitis from this article.

Price and analogues

The cost of Lazolvan tablets is approximately rubles for a package of 50 tablets and rubles for 20 tablets.

Among the drugs that contain a similar active ingredient (Ambroxol), we can highlight:

  • Ambrohexal (20 tablets – 109 rubles);
  • Ambrobene (20 tablets – 149 rubles);
  • Flavamed (20 tablets – 154 rubles);
  • Ambroxol (20 tablets – 44 rubles).

Reviews about tablets

The acquaintance with Lazolvan took place this summer. At first I had a slight cough, but I didn’t pay attention to it. A couple of days later a runny nose and fever appeared. At first the cough was dry, later it became wet. The therapist advised me to take Lazolvan tablets.

I took a tablet three times a day. I paid about 250 rubles for package No. 50. Already two days after taking it, there was a significant improvement. The cough, of course, still remained, but it was no longer as strong and painful.

The phlegm came off much easier. So, I recommend the drug! A little advice: it is better not to chew the tablet (it has an unpleasant taste), but to swallow it immediately with water.

Inna, 36 years old, Nizhny Novgorod

Recently I woke up with a severe cough, my throat was literally torn apart. My parents gave me Lazolvan. At first I didn’t want to drink it, since I’m allergic to many pills, but there was nowhere to go. The drug should be taken 1 tablet three times a day.

I took it before meals. After the first 24 hours, I could sleep normally at night. On the second day, almost all the phlegm came out with a cough, and it became much better.

During the reception, I drank a lot of water so that the phlegm would be better diluted. Thus, Lazolvan saved me in just a couple of days! Now I recommend him to my friends.

There is also a lot of useful and necessary information about cough medications in the following video.

Source: http://nektarin.su/zdorovje/preparaty/tabletki-lazolvan-instrukciya.html